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Forced vital capacityAbstract Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects
approximately 1%of the population, and pulmonary involvement is common.Themost commonpul-
monary manifestation is interstitial lung disease (ILD) which leads to pulmonary fibrosis. ILD is the
only complication of RA reported to be increasing in prevalence and it has been shown to account for
around 6% of all RA deaths. Surfactant proteins (SP-A, SP-B, SP-C and SP-D) play various impor-
tant roles in the lung. Serum SP-D levels reflected the disease activity of pulmonary fibrosis.
Aim of the study: To determine the clinical significance of surfactant protein D (SP-D), a useful
marker for evaluating interstitial lungdiseases and specifically in rheumatoid arthritis associated inter-
stitial lung disease patients.
Patients andmethods: Our patients were classified into 3 groups (Group 1: 18 patients had rheuma-
toid arthritis ILD; Group 2: 12 patients had rheumatoid arthritis without interstitial pulmonary dis-
ease; Group 3: 10 patients had idiopathic pulmonary fibrosis with no rheumatoid arthritis) and 20
healthy control subjects. Serum SP-D levels were assayed using a specific enzyme-linked immunosor-
bent assay for all studied groups.
Results: A highly significant difference was found between patients’ groups and the control group
regarding disease duration, serum aCCP, SP-D, serum CRP and RF being higher in patients’ group
(p< 0.01). However FVC was significantly lower in patients’ groups compared to the control group
(p< 0.05). Assessment of the diagnostic performance of SP-D assay revealed that the best cutoff for
discriminating rheumatoid patients with interstitial lung disease from those without interstitial lung
diseasewas 219 ng/mL.At this value, SP-Dhada diagnostic sensitivity of 94.2%, specificity 90%, neg-
ative predictive value 90%, positive predictive value 94.2% and efficiency 95%.
Conclusion: The serum SP-D level may be a useful marker for ILD especially in patients with
rheumatoid arthritis.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
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Rheumatoid arthritis (RA) is a chronic inflammatory disease
that affects approximately 1% of the population, and pul-
monary involvement is common. Furthermore, the lifespan
of RA patients is shortened by approximately 10 years, and
standardized mortality ratios for RA range from 1.28 to 3.0
[1]. Respiratory causes are a significant contributor to excess
mortality in patients with RA ranking as the second major
cause of death in this patient population. While the treatment
of rheumatoid articular disease has greatly improved in recent
years, as measured by disease activity and quality of life instru-
ments, these benefits have not extended to RA-associated lung
diseases [2].
A number of pulmonary manifestations are associated with
RA. The most common is interstitial lung disease (ILD) which
leads to pulmonary fibrosis (PF) during which the lung par-
enchyma is involved. ILD is not only the most common but
also the most serious form of lung involvement in RA. Radio-
graphic changes such as fibrosis, and physiological changes
such as restriction or decreased diffusing capacity on pul-
monary function testing, may precede symptoms by years;
however, once clinically apparent, ILD is associated with sig-
nificant mortality. Although it is common for ILD to be diag-
nosed concurrently with or after RA, a population based study
suggests that 3.5% of patients with RA were given a diagnosis
of ILD prior to the diagnosis of RA. Early studies identified a
high post-mortem incidence of RA–ILD and this was subse-
quently supported by high-resolution computed tomography
(HRCT) which confirmed that up to 25% of RA patients
had ILD. ILD is the only complication of RA reported to be
increasing in prevalence and it has been shown to account
for around 6% of all RA deaths [3].
Pulmonary surfactant is composed of phospholipids and
associated proteins. It covers the alveolar surface and main-
tains alveolar gas exchange during expiration. There are four
distinct proteins in pulmonary surfactant, which are desig-
nated surfactant proteins: SP-A, SP-B, SP-C and SP-D. These
surfactant proteins play various important roles in the lung,
such as maintaining the biophysical activity of the surfactant
and regulating surfactant homeostasis in the alveoli [4].
SP-D is a hydrophilic glycoprotein with a reduced molecu-
lar mass of 43 kDa. SP-D is produced and secreted by alveolar
type II epithelial cells and club cells structure which gives it the
ability to agglutinate pathogens, as well as aid in the clearance
of apoptotic cells, cellular debris, and foreign particles in the
lung. Recently, the SP-D levels in bronchoalveolar lavage
(BAL) fluids and the systemic circulation have been measured
in several lung diseases, including idiopathic pulmonary fibro-
sis. It was reported that the SP-D level in BAL fluids was
decreased in patients with pulmonary fibrosis, while the serum
SP-D level was significantly elevated [5].
This may be because the increased permeability of SP-D
results in an increase in alveolar to- vascular leakage of SP-
D in these patients. Increased serum SP-D levels were detected
in patients with idiopathic pulmonary fibrosis, interstitial
pneumonia with collagen diseases and pulmonary alveolar
proteinosis. In contrast, the serum SP-D levels in patients with
bacterial pneumonia were not elevated. Moreover, serum
SP-D levels reflected the disease activity of pulmonary fibrosis
[6].Pulmonary surfactant protein D (SP-D) is considered as a
candidate biomarker for the functional integrity of the lung
and for disease progression, which can be detected in serum.
The origin of SP-D in serum and how serum concentrations
are related to pulmonary concentrations under inflammatory
conditions is still unclear [7].
So this study aimed to determine the clinical significance of
surfactant protein D (SP-D), as a marker for evaluating
rheumatoid arthritis associated interstitial lung disease
patients.Patients and methods
This study was carried out at Chest and Internal Medicine
Departments, Faculty of Medicine, Zagazig University in the
period from March 2014 to February 2015.
Forty patients were recruited in this study. They were clas-
sified into 3 groups [Group 1: 18 patients (8 males and 10
females) had rheumatoid arthritis ILD; Group 2: 12 patients
(4 males and 8 females) had rheumatoid arthritis without inter-
stitial pulmonary disease; Group 3: 10 patients (7 males and 3
females) had interstitial pulmonary disease with no rheuma-
toid arthritis] in addition to 20 healthy control subjects (10
males and 10 females).Exclusion criteria
1. Cases that were diagnosed with chronic obstructive pul-
monary disease.
2. Cases that have had a respiratory tract infection during the
last three months prior to enrollment.
3. Patients with hepatic, renal, cardiovascular diseases, dia-
betes mellitus, cancer and systemic inflammatory disorders
other than rheumatoid disease.
4. Current smoker had been excluded from the study.
5. Any other rheumatologic disease had not been enrolled
except for rheumatoid arthritis.
All patients of Group 3 were diagnosed with idiopathic pul-
monary fibrosis (IPF), and had met American Thoracic Soci-
ety/European Respiratory Society (ATS/ERS) guidelines for
the diagnosis and management of IPF [8].
Rheumatoid arthritis patients (Groups 1 and 2) were diag-
nosed according to the American College of Rheumatology/
European League Against Rheumatism Classification Criteria
for RA as the following: [9]
Score of P6 points out of 10:
1. Joint involvement
a. One large joint (0 points).
b. Two to 10 large joints (1 point).
c. One to three small joints (2 points).
d. Four to 10 small joints (3 points).
e. More than 10 joints (at least one small) (5 points).
2. Serology
a. Negative rheumatoid factor (RF) and negative anti-
cyclic citrullinated peptide antibody (aCCP) (0 points).
b. Low positive RF or aCCP (>3 times the upper limit of
normal (2 points).
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normal (3 points).
3. Acute phase reactants
a. Normal C-reactive protein and normal erythrocyte sed-
imentation rate (0 points).
b. Abnormal C-reactive protein or abnormal erythrocyte
sedimentation rate (1 point).
4. Duration of symptoms
a. <6 weeks (0 points).
b. P6 weeks (1 point).
Group 1 patients had met the criteria of the American Col-
lege of Rheumatology/European League Against Rheumatism
Classification Criteria for RA [9] plus radiological evidence of
interstitial lung disease by high resolution computed tomogra-
phy (HRCT).
Written informed consents were obtained from all subjects.
All patients underwent a detailed symptom enquiry, physi-
cal examination and investigations including age, disease dura-
tion, CRP levels, rheumatoid factor, arterial blood gases,
serum cyclic citrullinated peptide antibody, a chest radiograph
(postero-anterior view), high resolution CT scan (HRCT) and
pulmonary function tests as forced vital capacity (FVC).
The serum surfactant protein D (SP-D) levels were mea-
sured in the peripheral venous blood samples in all cases.
The serum samples, which were collected from the patients
or healthy volunteers at their initial visits, were stored at
80 C until use and subsequently analyzed in a blinded fash-
ion with regard to the patient’s clinical status. Each serum
sample was analyzed for the following:
1. Measurement of serum surfactant protein D (SP-D) was
done by an enzyme-linked immunosorbent assay (ELISA).
SP-D was measured by a commercially available ELISA kit
(Endogen, MA).
2. Measurement of serum highly sensitive-CRP, rheumatoid
factor (RF) and aCCP was done using an available com-
mercial kit (ROCHE Diagnostics’, COBAS 6000 auto ana-
lyzer, Germany). The measurement method used is based
on a particle enhanced immunonephelometry and
chemiluminescence assay and quality control is done before
test measurement.
Spirometric values were measured using a spirometer. The
best value of three maneuvers was expressed as a percentage
of the predicted value and as absolute value. We concentrate
on FVC values in this study.
Arterial blood gases analysis was done on APL auto-
analyzer. Quality control was done before test measurement.
High resolution CT scan (HRCT) was done in all patients
to reach to the diagnosis of ILD.
Statistical analysis
Differences in ages or the levels of the various serum markers
between subject groups were analyzed using ANOVA one way
test, Student’s t test or Wilcoxon’s rank sum test, if applicable.
The levels of these serum markers were further analyzed usingreceiver operating characteristic (ROC) curves to determine
the cut-off levels that resulted in the optimal diagnostic accu-
racy for each marker. Positive quantitative differences between
groups were tested by the Chi-square test for goodness of fit or
Fisher’s exact probability test. The correlation coefficients for
these markers were calculated using Spearman’s correlation
coefficient by rank. Significance was defined as p< 0.05.
Results
Table 1 shows descriptive study for age and sex in patients’
groups and control group.
Table 2 shows that a highly statistical significant difference
was found between patients’ groups and control group regard-
ing disease duration, serum aCCP, SP-D, serum CRP and RF
being higher in patients’ groups (p< 0.01). However FVC
were significantly lower in patients’ groups compared to the
control group (p< 0.05).
Table 3 shows that a highly statistical significant difference
was found between Group 1 vs Group 2 and Group 3 as
regards SP-D (p< 0.01). However there was a significant dif-
ference between Group 2 vs Group 1 and Group 3 as regards
FVC (p< 0.05). There was a very high statistical significant
difference between Group 1 and Group 2 vs Group 3 as
regards CRP, RF and aCCP.
Table 4 clarified that the comparison between control
group vs all patient, control group vs Group 1, control group
vs Group 3, Group 1 vs Group 2 and Group 2 vs Group 3 was
highly significant (p< 0.01), while the comparison between
control group vs Group 2 and Group 1 vs Group 3 was non
significant.
Table 5 shows that there was a highly negative correlation
between SP-D and FVC in Group 1 (p< 0.01) and a positive
correlation between SP-D and CRP, RF, aCCP in Group 1
(p< 0.05), while there was a positive correlation between
SP-D and RF in Group 2 (p< 0.05) and a highly negative cor-
relation between SP-D and FVC in Group 3 (p< 0.01).
Fig. 1 shows receiver-operating characteristic (ROC) curve
that was used for the assessment of the diagnostic performance
of SP-D assay which revealed that the best cutoff value for dis-
criminating rheumatoid patients with interstitial lung disease
from those without interstitial lung disease was 219 ng/mL.
At this value, SP-D had a diagnostic sensitivity of 94.2%,
specificity 90%, negative predictive value 90%, positive predic-
tive value 94.2% and efficiency 95%.Discussion
ILD is one of the most severe complications in rheumatoid
arthritis, and often carries a poor prognosis in spite of various
therapies. The therapy for rheumatoid disease differs widely
depending on the existence or activity of ILD. Therefore, it
is important to evaluate the existence and severity of ILD
when treating patients with rheumatoid arthritis. In general,
chest radiography, lung function testing and blood gas analysis
are usually used in the management of ILD in patients with
rheumatoid arthritis [10]
In the present study, the serum SP-D level of rheumatoid
arthritis patients with ILD (Group 1) was significantly elevated
compared with those without ILD (Group 2). The incidence of
Table 1 Descriptive study for age and sex.
Control group Group 1 Group 2 Group 3 ANOVA p
Age (mean ± SD) 42 ± 14 49 ± 11 51 ± 6 47 ± 12 1.89 0.14
v2 p
Sex Male n (%) 10 (50%) 8 (44.4%) 4 (33.3%) 7 (70%) 3.092 0.37
Female n (%) 10 (50%) 10 (55.6%) 8 (66.7%) 3 (30%)
v2: Chi-square test.
Table 2 Descriptive and comparative statistics of investigations in patients’ group vs control group using student’s t test for
parametric data and Wilcoxon’s rank sum test for non parametric data.
Parameter Control group (n= 20)
X± SD/ median (IQR)
All patients (n= 40)
X± SD/median (IQR)
p
Disease duration months 0 39 (7–52) p< 0.01
CRP (mg/L) 3.1 ± 1.5 32.4 ± 16.3 p< 0.01
RF (mg/L) 3.2 ± 6.2 46.4 ± 82.2 p< 0.01
FVC (% of expected) 95 (91–107) 64 (52–85) p< 0.05
aCCP (ng/ml) 4.4 ± 2.1 23.2 ± 15.6 p< 0.01
SP-D (ng/ml) 31.0 ± 12.4 61.7 ± 122.6 p< 0.01
IQR (interquartile range).
Table 3 Descriptive and comparative statistics of investigations in patients’ groups using ANOVA test for parametric data and
Wilcoxon’s rank sum test for non parametric data.
Parameter Group 1 X ± SD/median (IQR) Group 2 X ± SD/median (IQR) Group 3 X ± SD/median (IQR) p
Disease duration months 45 (21–52) 34 (22–48) 28 (12–36) p< 0.05
CRP (mg/L) 42.2 ± 14.5 36.4 ± 12.8 21.2 ± 6.6 p= 0.001
RF (mg/L) 58 ± 24.2 49.4 ± 26.4 6.2 ± 4.1 p< 0.001
FVC (% of expected) 57 (52–72) 89 (78–99) 61 (48–88) p< 0.05
aCCP (ng/ml) 26.2 ± 16.4 25.4 ± 18.2 7.2 ± 4.1 p= 0.006
SP-D (ng/ml) 204.2 ± 65 58.6 ± 14.6 91 ± 42.1 p< 0.01
Table 4 Statistical comparison of serum SP-D between
different studied groups using Wilcoxon’s rank sum test.
Groups z p
Control vs all patients 4.86 <0.01
Control vs Group 1 3.31 <0.01
Control vs Group 2 0.87 >0.05
Control vs Group 3 2.95 <0.01
Group 1 vs Group 2 2.42 <0.01
Group 1 vs Group 3 0.23 >0.05
Group 2 vs Group 3 2.56 <0.01
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elevated SP-D level than in those with a normal level. Further-
more, the serum SP-D level was inversely correlated with %
FVC which is in agreement with the findings of Tracy et al.
[11].
These results suggest that the serum SP-D level is a serum
marker for ILD and reflects the severity of ILD in patients
with rheumatoid arthritis. In this study, the diagnosis of ILD
was made on the basis of the findings of chest radiography,
computed tomography of the chest and lung function tests.
However, there may be patients with minor respiratory crepi-
tations, probably due to fibrosis, who do not have abnormal
values in these examinations.
A highly significant difference was found between patients’
group and control group regarding disease duration, serum
aCCP, SP-D, serum CRP and RF being higher in patients’
group (p< 0.01). However FVC was significantly lower in
patients’ group compared to the control group (p< 0.05).
This reflects the sensitivity and specificity of this marker and
the good choice of patient intensifying the exclusion criteria
for our research, these results are in agreement with those of
Sato et al. [12].The comparison between control vs all patient in SP-D
levels was highly significant (p< 0.01) that indicates a high
sensitivity and selectivity of the test. The comparison between
control group vs rheumatoid arthritis with interstitial pul-
monary disease SP-D levels was highly significant (p< 0.01),
that totally agreed with most of other researches about SP-D.
The comparison between Rheumatoid arthritis with
interstitial pulmonary disease group vs group of rheumatoid
arthritis with no interstitial pulmonary disease in SP-D levels
Table 5 Correlation analysis between SP-D and different studied parameters in different studied groups using Spearman’s rank
correlation test.
Parameter Group
Control Group 1 Group 2 Group 3
rs p rs p rs p rs p
Disease duration months . . . . . . 0.19 >0.05 0.26 >0.05 0.36 >0.05
CRP (mg/L) 0.25 >0.05 0.56 <0.05 0.49 >0.05 0.34 >0.05
RF (mg/L) 0.07 >0.05 0.57 <0.01 0.59 <0.05 0.13 >0.05
FVC (% of expected) 0.18 >0.05 0.65 <0.01 0.12 >0.05 0.72 <0.01
aCCP (ng/ml) 0.13 >0.05 0.59 <0.05 0.50 >0.05 0.17 >0.05
Figure 1 ROC curve analysis showing the diagnostic perfor-
mance of SP-D for discriminating rheumatoid patients with
interstitial lung disease from those without interstitial lung disease.
AUC: area under cruve. NDL: non diagnostic line.
Clinical significance of serum surfactant protein D 483was highly significant p< 0.01. Similarly the comparison
between the group with rheumatoid arthritis with no intersti-
tial pulmonary disease vs the group with interstitial pulmonary
disease with no rheumatoid arthritis was highly significant
p< 0.01. This allows us to make a cut off in the ROC curve
that was SP-D levels 219 ng/mL between rheumatoid arthritis
with interstitial pulmonary disease group vs the group with
rheumatoid arthritis with no interstitial pulmonary disease.
This cut off is so essential for confirming interstitial pulmonary
disease in rheumatoid patients making it a unique marker.
While the comparison between control vs the group with
rheumatoid arthritis with no interstitial pulmonary disease
and the group with Rheumatoid arthritis with interstitial pul-
monary vs the group with interstitial pulmonary disease with
no rheumatoid arthritis in SP-D levels was non significant
(p> 0.05). This result was surprising as this omit the effect
of rheumatoid activity in increasing the marker making the
interstitial disease to take the upper hand in this marker this
with disagree of Kristiansen et al. [10] that stated that rheuma-
toid arthritis increase this marker and illustrate that marker
increase in disease activity that not confirmed in our study.
Assessment of the diagnostic performance of SP-D assay
revealed that the best cutoff for discriminating rheumatoid
patients with interstitial lung disease from those without inter-
stitial lung disease was 219 ng/mL. At this value, SP-D had adiagnostic sensitivity of 94.2%, specificity 90%, negative pre-
dictive value 90%, positive predictive value 94.2% and effi-
ciency 95%, which we aimed in the study.
In conclusion, we have demonstrated the elevation of serum
SP-D level in rheumatoid patients with interstitial lung disease.
SP-D may be a useful marker for evaluating earlier ILD in
patients with rheumatoid arthritis. However, this study was
undertaken with a small patient population. Further studies
are needed to clarify the usefulness of SP-D in rheumatoid
arthritis patients.
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